Nintedanib

Generic Name
Nintedanib
Brand Names
Ofev, Vargatef, Nintedanib Accord
Drug Type
Small Molecule
Chemical Formula
C31H33N5O4
CAS Number
656247-17-5
Unique Ingredient Identifier
G6HRD2P839
Background

Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC). It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis treatment options, nintedanib is currently one of only tw...

Indication

Nintedanib is indicated for the treatment of idiopathic pulmonary fibrosis (IPF) and to slow declining pulmonary function in patients with systemic sclerosis-associated interstitial lung disease. It is also indicated for the treatment of chronic fibrosing interstitial lung diseases with a progressive phenotype.
...

Associated Conditions
Idiopathic Pulmonary Fibrosis (IPF), Respiratory Function Impaired, Chronic Progressive Fibrosing Interstitial Lung Disease, Locally advanced Non-Small Cell Lung Carcinoma (NSCLC), Locally recurrent Non-Small Cell Lung Carcinoma (NSCLC), Metastatic Non-Small Cell Lung Carcinoma (NSCLC)
Associated Therapies
-
Clinical Trials
Related News

Adherence to Nintedanib Among Idiopathic Pulmonary Fibrosis Patients

Completed
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Drug: Nintedanib
First Posted Date
2021-08-26
Last Posted Date
2024-04-19
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
1798
Registration Number
NCT05022784
Locations
🇺🇸

Medicus Economics, LCC, Milton, Massachusetts, United States

Efficacy of Nintedanib for Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Patients

First Posted Date
2021-07-26
Last Posted Date
2022-07-26
Lead Sponsor
Dr. Romain Lazor
Target Recruit Count
48
Registration Number
NCT04976036
Locations
🇨🇭

Respiratory medicine Department, Lausanne University Hospital, Lausanne, Vaud, Switzerland

Drug-drug Interaction Study With GLPG4716 and Nintedanib and Pirfenidone in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Pirfenidone
Drug: Nintedanib
Drug: GLPG4716
First Posted Date
2021-07-21
Last Posted Date
2022-06-02
Lead Sponsor
Galapagos NV
Target Recruit Count
58
Registration Number
NCT04971746
Locations
🇩🇪

Nuvisan GmbH, Neu-Ulm, Germany

To Evaluate Drug-drug Interactions Between DWN12088 and Pirfenidone or Nintedanib in Healthy Volunteers

First Posted Date
2021-05-17
Last Posted Date
2021-09-23
Lead Sponsor
Daewoong Pharmaceutical Co. LTD.
Target Recruit Count
48
Registration Number
NCT04888715
Locations
🇰🇷

Cha Unitersity Bundang Medical Center, Seongnam-si, Korea, Republic of

Pirfenidone vs. Nintedanib for Fibrotic Lung Disease After Coronavirus Disease-19 Pneumonia

Phase 4
Active, not recruiting
Conditions
Novel Coronavirus-induced Lung Fibrosis
Interventions
Drug: Pirfenidone
Drug: Nintedanib
First Posted Date
2021-04-22
Last Posted Date
2022-10-03
Lead Sponsor
Post Graduate Institute of Medical Education and Research, Chandigarh
Target Recruit Count
48
Registration Number
NCT04856111
Locations
🇮🇳

Postgraduate Institute of Medical Education and Research, Chandigarh, India

An Expanded Access Program in Belgium to Provide Nintedanib to People With Lung Diseases Called Non-IPF ILDs Who Have no Alternative Treatment Options

First Posted Date
2021-02-04
Last Posted Date
2022-09-09
Lead Sponsor
Boehringer Ingelheim
Registration Number
NCT04739150
Locations
🇧🇪

Aalst - HOSP Onze-Lieve-Vrouw, Aalst, Belgium

🇧🇪

ULB Hopital Erasme, Anderlecht, Belgium

🇧🇪

Ziekenhuis Netwerk Antwerpen (ZNA) - Campus Middelheim, Antwerpen, Belgium

and more 11 locations

INREAL - Nintedanib for Changes in Dyspnea and Cough in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease (ILD) With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation

Completed
Conditions
Lung Diseases, Interstitial
Interventions
Drug: Nintedanib
First Posted Date
2021-01-11
Last Posted Date
2024-11-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
108
Registration Number
NCT04702893
Locations
🇩🇪

Universitätsklinikum Aachen, AöR, Aachen, Germany

🇩🇪

Pneumologische Praxis Dr. Löh, Bad Homburg, Germany

🇩🇪

Vivantes Klinikum Neukölln, Berlin, Germany

and more 18 locations

The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19

First Posted Date
2020-11-06
Last Posted Date
2024-07-30
Lead Sponsor
Icahn School of Medicine at Mount Sinai
Target Recruit Count
121
Registration Number
NCT04619680
Locations
🇺🇸

Emory Healthcare Network, Atlanta, Georgia, United States

🇺🇸

Baylor University Medical Center Dallas, Dallas, Texas, United States

🇺🇸

Baylor College of Medicine, Houston, Texas, United States

and more 4 locations

Post-marketing Surveillance of Ofev Capsules in Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype in Japan

Active, not recruiting
Conditions
Lung Diseases, Interstitial
Interventions
Drug: Nintedanib
First Posted Date
2020-09-23
Last Posted Date
2024-11-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
425
Registration Number
NCT04559581
Locations
🇯🇵

Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan

Safety and Effectiveness of Nintedanib in Korean Patients

Completed
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Drug: Nintedanib
First Posted Date
2020-08-25
Last Posted Date
2024-03-12
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
70
Registration Number
NCT04525547
Locations
🇰🇷

Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of

🇰🇷

Inje University Ilsan Paik Hospital, Gyeonggi-do, Korea, Republic of

🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

and more 19 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy